HomeCONGRESS

CONGRESS

View Category
Coronary disease

ACC 2022 | IVVE

This randomized study aimed at assessing the flu vaccine vs placebo in patients with cardiac failure.  It included...
solaci -
Learn More
Acute coronary syndromes

ACC 2022 | PROMPT-HF

Patients with cardiac failure with reduced ejection fraction (HFrEF) are sub treated when you look at guideline-directed...
solaci -
Learn More
Structural heart disease

ACC 2022 | APOLLO

Lipoprotein a (Lp a) is an important risk factor for atherothrombosis and atherosclerotic cardiovascular disease, but it...
solaci -
Learn More
Coronary disease

ACC 2022 – EDIT-CMD

Roughly 40% of patients receiving a coronary angiography for stable angina (angina episodes twice a week despite...
solaci -
Learn More
Acute coronary syndromes

ACC 2022 – Complete Trial QoL: Complete Revascularization in STEMI

The COMPLETE study has shown complete revascularization in STEMI reduces cardiovascular mortality or new AMI, which generated...
solaci -
Learn More
Pharmacology

ACC 2022 | VALOR-HCM: Mavacamten in Adults with Symptomatic Obstructive HCM Eligible for Septal Reduction Therapy

Roughly 50% of hypertrophic cardiomyopathies (HCM) are obstructive, and of this percentage, most of symptoms can be...
solaci -
Learn More
Pharmacology

ACC 2022 – POISE-3: Tranexamic Acid, Bleeding and Cardiovascular Events in Non-Cardiac Surgeries

Tranexamic Acid is an antifibrinolytic which has been shown to reduce bleeding in orthopedic patients and cardiac...
solaci -
Learn More
ACC 2022

ACC 2022

Here are the most important scientific articles of the ACC 2022 Congress. If you cannot view the articles,...
solaci -
Learn More